The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

The Globe and Mail has
updated our Stock Quote Pages
You are about to experience the newly designed Stock Quote Pages format. With the new layout, you'll enjoy a more in-depth look at the companies you're following and pages that are easier to navigate. This Editors' blog post explains why we've made these changes.

 

AbbVie Inc

NYSE: ABBV
Last

(U.S.) $69.73

Today's change0.00 0.00%
Updated August 3 4:01 PM EDT. Delayed by at least 15 minutes.
 

AbbVie Inc

NYSE: ABBV
Last

(U.S.) $69.73

Today's change0.00 0.00%
Updated August 3 4:01 PM EDT. Delayed by at least 15 minutes.

AbbVie Inc closed at (U.S.)$69.73.

Over the last five days, shares have gained 0.56% and are currently 2.61% off of the 52-week high. Shares have outperformed the S&P 500 by 23.89% during the last year.

Key company metrics

  • Open(U.S.) $0.00
  • Previous close(U.S.) $69.73
  • High--
  • Low--
  • Bid / Ask(U.S.) $68.05 / (U.S.) $73.38
  • YTD % change+6.56%
  • Volume0
  • Average volume (10-day)8,181,359
  • Average volume (1-month)8,410,253
  • Average volume (3-month)9,585,762
  • 52-week range(U.S.) $51.37 to (U.S.) $71.60
  • Beta--
  • Trailing P/E54.54×
  • P/E 1 year forward16.37×
  • Forward PEG0.98×
  • Indicated annual dividend(U.S.) $2.04
  • Dividend yield2.93%
  • Trailing EPS(U.S.) $1.28
Updated August 3 4:01 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+9.93%

Based on its net profit margin of 9.93%, AbbVie Inc is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.00%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q2/2015Q1/2015Q4/2014Q3/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedJun 30, 201506/30/2015Mar 31, 201503/31/2015Dec 31, 201412/31/2014Sep 30, 201409/30/2014
Revenue5,4755,0405,4525,019
Total other revenue--------
Total revenue5,4755,0405,4525,019
Gross profit4,5764,0984,3333,955
Total cost of revenue8999421,1191,064
Total operating expense3,3673,3535,8674,059
Selling / general / administrative1,4691,3543,3411,595
Research & development965811879812
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)3424628315
Other operating expenses, total----500250
Operating income2,1081,687-415960
Interest income (expense), net non-operating---132-139-148
Gain (loss) on sale of assets--------
Other--------
Income before tax1,6781,396-1,037687
Income after tax1,3661,022-810506
Income tax, total312374-227181
Net income1,3661,022-810506
Total adjustments to net income--------
Net income before extra. items1,3661,022-810506
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items1,3661,022-810506
Inc. avail. to common incl. extra. items1,3661,022-810506
Diluted net income1,3661,022-810506
Dilution adjustment------0
Diluted weighted average shares1,6331,6081,5951,610
Diluted EPS excluding extraordinary itemsvalue per share0.840.64-0.510.31
Dividends per sharevalue per share0.510.510.420.42
Diluted normalized EPSvalue per share0.860.77-0.490.51